Singapore markets closed

Baxter International Inc. (BAX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
46.28+0.59 (+1.29%)
At close: 04:00PM EST
44.89 -1.39 (-3.00%)
Pre-market: 04:02AM EST
Full screen
Trade prices are not sourced from all markets
Previous close45.69
Open45.89
Bid0.00 x 1100
Ask0.00 x 1400
Day's range45.29 - 46.37
52-week range43.25 - 89.70
Volume7,550,551
Avg. volume5,329,878
Market cap23.331B
Beta (5Y monthly)0.59
PE ratio (TTM)23.14
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.16 (2.52%)
Ex-dividend date01 Dec 2022
1y target estN/A
  • Business Wire

    Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure

    EDEN PRAIRIE, Minn. & DEERFIELD, Ill., February 01, 2023--Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system. Miro

  • Business Wire

    Baxter to Host Fourth-Quarter 2022 Financial Results Conference Call for Investors

    DEERFIELD, Ill., January 11, 2023--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2022 financial results on Thursday, February 9, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information.

  • Business Wire

    Baxter Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholders

    DEERFIELD, Ill., January 06, 2023--Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced a comprehensive strategic roadmap to meaningfully enhance its operational effectiveness, drive toward improved long-term performance, accelerate innovation and create additional value for all stakeholders. These changes include the plan to spin off the company’s Renal Care and Acute Therapies global business units (GBUs) into an independent, publicly traded company; a simpli